{"title":"增强渗透滞留效应--用于纳米粒子介导的抗癌诊断或治疗的建模和成像方法","authors":"Suresh P.K.","doi":"10.2174/0115701808306902240604071741","DOIUrl":null,"url":null,"abstract":"\n\nThis perspective focuses on the hyper-permeable vasculature, contributing to the passive\naccumulation of drugs or NP-drug combinations through the paracellular and/or transcellular pathways.\nThis unique, cardinal, pathological feature of the vasculature in solid tumors is a major determinant\nfor the entry of anti-cancer macromolecules, with longer drug retention, attributable to imperfections\nin the lymphatic drainage system. However, the desmoplastic reaction, another challenge in\nterms of drug delivery, is attributable to the collagen-dense, heterogeneous accumulation of stromal\ncomponents in the Tumour Microenvironment (TME). Thus, the consequent increases in the Interstitial\nFluid Pressure (IFP) have been determined by experimental and computational techniques. This\nback-flow can contribute to decrements in the drug/NP-drug conjugate reaching the tumour site,\nwarranting strategies to be adopted that can lower this pressure. However, the translational potential\nof the EPR-effect-mediated drug delivery in humans is limited. The tumour-specific, spatiotemporal\ndifferences in the EPR effect require human-relevant tumour models as well as their analysis based\non advanced imaging, including MRI-based studies. This development, validation, and refinement of\nan iterative strategy can lead to the optimization of such customized models for personalised, tailormade\nmedicine.\n","PeriodicalId":18063,"journal":{"name":"Letters in Drug Design & Discovery","volume":"8 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Enhanced Permeation Retention Effect - Modeling and Imaging Approaches for Nanoparticle-Mediated Anti-cancer Diagnostics or Therapy\",\"authors\":\"Suresh P.K.\",\"doi\":\"10.2174/0115701808306902240604071741\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nThis perspective focuses on the hyper-permeable vasculature, contributing to the passive\\naccumulation of drugs or NP-drug combinations through the paracellular and/or transcellular pathways.\\nThis unique, cardinal, pathological feature of the vasculature in solid tumors is a major determinant\\nfor the entry of anti-cancer macromolecules, with longer drug retention, attributable to imperfections\\nin the lymphatic drainage system. However, the desmoplastic reaction, another challenge in\\nterms of drug delivery, is attributable to the collagen-dense, heterogeneous accumulation of stromal\\ncomponents in the Tumour Microenvironment (TME). Thus, the consequent increases in the Interstitial\\nFluid Pressure (IFP) have been determined by experimental and computational techniques. This\\nback-flow can contribute to decrements in the drug/NP-drug conjugate reaching the tumour site,\\nwarranting strategies to be adopted that can lower this pressure. However, the translational potential\\nof the EPR-effect-mediated drug delivery in humans is limited. The tumour-specific, spatiotemporal\\ndifferences in the EPR effect require human-relevant tumour models as well as their analysis based\\non advanced imaging, including MRI-based studies. This development, validation, and refinement of\\nan iterative strategy can lead to the optimization of such customized models for personalised, tailormade\\nmedicine.\\n\",\"PeriodicalId\":18063,\"journal\":{\"name\":\"Letters in Drug Design & Discovery\",\"volume\":\"8 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Letters in Drug Design & Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115701808306902240604071741\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Letters in Drug Design & Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115701808306902240604071741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Enhanced Permeation Retention Effect - Modeling and Imaging Approaches for Nanoparticle-Mediated Anti-cancer Diagnostics or Therapy
This perspective focuses on the hyper-permeable vasculature, contributing to the passive
accumulation of drugs or NP-drug combinations through the paracellular and/or transcellular pathways.
This unique, cardinal, pathological feature of the vasculature in solid tumors is a major determinant
for the entry of anti-cancer macromolecules, with longer drug retention, attributable to imperfections
in the lymphatic drainage system. However, the desmoplastic reaction, another challenge in
terms of drug delivery, is attributable to the collagen-dense, heterogeneous accumulation of stromal
components in the Tumour Microenvironment (TME). Thus, the consequent increases in the Interstitial
Fluid Pressure (IFP) have been determined by experimental and computational techniques. This
back-flow can contribute to decrements in the drug/NP-drug conjugate reaching the tumour site,
warranting strategies to be adopted that can lower this pressure. However, the translational potential
of the EPR-effect-mediated drug delivery in humans is limited. The tumour-specific, spatiotemporal
differences in the EPR effect require human-relevant tumour models as well as their analysis based
on advanced imaging, including MRI-based studies. This development, validation, and refinement of
an iterative strategy can lead to the optimization of such customized models for personalised, tailormade
medicine.